Canada's Healwell AI fiscal 2025 revenue jumps 427%

Healwell Al

19/03/2026 11:08

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * Canada healthcare AI firm's fiscal 2025 revenue grew 427% yr/yr to record levels
    * Company posted first full yr of positive Adjusted EBITDA after prior yr loss
    * Healwell transitioned to pure-play AI and software, generating C$9.7 mln in divestment proceeds

    
    Outlook
  
    * Healwell targets exit run-rate Adjusted EBITDA margin of about 10% in 2026
    * Company aims to scale globally and deepen AI adoption across its installed base in 2026
    * Healwell expects operating leverage as Orion Health integration synergies are realized and AI deployments scale

    
    Result Drivers
  
    * ORION HEALTH ACQUISITION - Co said acquisition of Orion Health contributed significantly to revenue growth in Q4-2025
    * ENTERPRISE AI DEPLOYMENTS - Co cited scaling enterprise AI deployments, including government and U.S. HIE contracts, as key to platform adoption and revenue gains
    * STRATEGIC DIVESTMENTS - Transition to pure-play AI and software business and C$9.7 mln in divestment proceeds supported focus and balance sheet

    
Company press release:  ID:nNFC98Xfc7 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4                  C$32.22    
 Revenue             mln       
 Q4 Net              -C$1.79    
 Income              mln       
 Q4 Gross            C$17.64    
 Profit              mln       
 Q4                  -C$3.71    
 Income              mln       
 From                          
 Operatio                      
 ns                            
 Q4 Net              -C$7.05    
 Income              mln       
 Cont Ops                      
 Q4                  C$21.36    
 Operatin            mln       
 g                             
 Expenses                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
    * Wall Street's median 12-month price target for Healwell Al Inc is C$2.88, about 209.1% above its March 18 closing price of C$0.93

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)